Additional Details
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
MD Anderson Cancer CenterHouston TX. 77030View Details -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteMontréal QC. H2X 0A9View Details -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteEdmonton AB. T6G 2C8View Details -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteSherbrooke QC. J1H 5N4View Details -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Research SiteVancouver BC. V6Z 2K5View Details -
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of California San FranciscoSan Francisco CA. 94143View Details -
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of MichiganAnn Arbor MI. 48109View Details -
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of KansasKansas City KS. 66103View Details -
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of Colorado DenverAurora CO. 80045View Details -
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Northwell HealthNew Hyde Park NY. 11042View Details -
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Summit HealthBend OR. 97701View Details -
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Legacy Research InstitutePortland OR. 97210View Details -
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
AnMed HealthAnderson SC. 29621View Details -
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Pulmonary Associates of Richmond, Inc.Richmond VA. 23230View Details -
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Northern Westchester HospitalMount Kisco NY. 10549View Details -
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Mount Sinai Hospital-New York-52529New York NY. 10029View Details -
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
University of Utah Health Sciences CenterSalt Lake City UT. 84132View Details -
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Pulmonary and Sleep Center of the ValleyMcAllen TX. 78504View Details -
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Renown Regional Medical CenterReno NV. 89502View Details -
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
University of Oklahoma-Oklahoma City-59108Oklahoma City OK. 73019View Details